BPC-157 has been around since 1992
As of mid-2026, BPC-157 is not on the FDAs approved 503B bulk-drug substances list, and the Pharmacy Compounding Advisory Committee is scheduled to take it up at an upcoming meeting in July 2026
[16] [18] Healthcare providers should weigh the anticipated benefits against potential risks and consider alternative routes or lower doses when appropriate
Standardized dosing protocols, validated outcome measures, and comprehensive safety monitoring would establish the evidence base necessary for informed clinical decision-making
Any papers resulting from these two trials do not appear to be indexed in major global databases like PubMed, and its not clear if they were ever published in peer-reviewed journals
However, it did improve anxiety symptoms in the patients.[ref] A meta-analysis of clinical trials using 900 2700 mg/day showed that NAC may improve hearing loss (noise-induced).[ref] Keep in mind that these studies involved patients who were likely to have increased glutathione use